Technology Appraisal Committee Meeting (Committee [A])

Minutes: [Confirmed]

Date and Time: Tuesday 8 August 2017

Venue:
National Institute for Health and Care Excellence
10 Spring Garden
London
SW1A 2BA

Present:
1. Chair Jane Adam  Present for all notes
2. Professor Iain Squire  Present for all notes
3. Dr Graham Ash  Present for all notes
4. Dr Rita Faria  Present for all notes
5. Dr Rachel Hobson  Present for all notes
6. Dr Anne McCune  Present for all notes
7. Dr Brian Shine  Present for all notes
8. Dr Ian Bernstein  Present for all notes
9. Mrs Sarah Parry  Present for all notes
10. Ms Pamela Rees  Present for all notes
11. Ms Ellen Rule  Present for all notes
12. Dr Paul Robinson  Present for all notes
13. Mr David Evans  Present for all notes
14. Mr Stephen Sharp  Present for all notes
15. Professor Olivia Wu  Present for all notes
16. Dr John Watkins  Present for all notes
17. Dr Nerys Woolacott  Present for all notes
18. Professor John McMurray  Present for all notes

In attendance:

Meindert Boysen  Programme Director, National Institute for Health and Care Excellence  Present for all notes
Janet Robertson  Associate Director, National Institute for Health and Care Excellence  Present for all notes
Thomas Feist  Project Manager, National Institute for  Present for all notes
<table>
<thead>
<tr>
<th>Name</th>
<th>Position or Role</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marcia Miller</td>
<td>Technology Appraisal Administrator, National Institute for Health and Care Excellence</td>
<td>Present for all notes</td>
</tr>
<tr>
<td>Hamish Lungaria</td>
<td>Technical Analyst, National Institute for Health and Care Excellence</td>
<td>Present for all notes</td>
</tr>
<tr>
<td>Zoe Charles</td>
<td>Technical Adviser, National Institute for Health and Clinical Excellence</td>
<td>Present for all notes</td>
</tr>
<tr>
<td>Mrs Gwyneth Fraser</td>
<td>Patient expert nominated by Breast Cancer Now</td>
<td>Present for notes 7 to 15</td>
</tr>
<tr>
<td>Catherine Priestly</td>
<td>Patient expert nominated by Breast Cancer Now</td>
<td>Present for notes 7 to 15</td>
</tr>
<tr>
<td>Dr Daniel Rea</td>
<td>Nominated by RCP</td>
<td>Present for notes 7 to 15</td>
</tr>
<tr>
<td>Keith Cooper</td>
<td>ERG, Southampton Health Technology Assessment Centre</td>
<td>Present for notes 7 to 15</td>
</tr>
<tr>
<td>Joanne Picot</td>
<td>ERG, Southampton Health Technology Assessment Centre</td>
<td>Present for notes 7 to 15</td>
</tr>
<tr>
<td>Neelam Kalita</td>
<td>ERG, Southampton Health Technology Assessment Centre</td>
<td>Present for notes 7 to 15</td>
</tr>
<tr>
<td>Mr Pete Fraser</td>
<td>Patient carer</td>
<td>Present for all notes 7 to 15</td>
</tr>
<tr>
<td>Helen Barnett</td>
<td>NICE, Appraisal Editors</td>
<td>Present for all notes</td>
</tr>
<tr>
<td>Minal Bakhai</td>
<td>Committee A Member</td>
<td></td>
</tr>
<tr>
<td>Chloe Kastoryano</td>
<td>NICE, PPIP</td>
<td>Present for notes</td>
</tr>
<tr>
<td>Min ven teo</td>
<td>NICE Scholar</td>
<td>Present for notes</td>
</tr>
</tbody>
</table>
Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of Fulvestrant for untreated hormone-receptor positive locally advanced or metastatic breast cancer [ID951]

2. The Chair informed the Committee of the non-public observers at this meeting: Mr Peter Fraser, Helen Barnett, Minal Bakhai, Min ven teo, Chloe Kastoryano and Joshua South

3. Rui Martins, Olu Onyimadu, Wendy Gainsford and Adam Storrow

4. Apologies were received from

Notes from the last meeting

6. The minutes of the last meeting were agreed with no changes.

Appraisal of Fulvestrant for untreated hormone-receptor positive locally advanced or metastatic breast cancer [ID951]

Part 1 – Open session

7. The Chair welcomed the invited experts: Keith Cooper, Mrs Gwyneth Fraser, Neelam Kalita, Joanne Picot, Dr Daniel Rea and Catherine Priestly to the meeting and they introduced themselves to the Committee.

8. The Chair welcomed company representatives from AstraZeneca to the meeting.

9. The Chair asked all Committee members to declare any relevant interests

9.1. Dr Jane Adam, Dr Graham, Dr Rita Faria, Dr Rachel Hobson, Dr Anne McCune, Dr Brian Shine, Dr Ian Bernstein, Mrs Sarah Parry, Ms Pamela
Rees, Ms Ellen Rule, Dr Paul Robinson, Mr David Evans, Mr Stephen Sharp, Professor Olivia Wu, Dr John Watkins, Dr Nerys Woolacott and Professor John McMurray all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Fulvestrant for untreated hormone-receptor positive locally advanced or metastatic breast cancer [ID951]

9.2. Professor John McMurray declared a non-personal specific financial interest as he has his university receives funding from company/comparator for heart disease trails.

9.2.1 It was agreed that this declaration would not prevent Professor John McMurray from participating in this section of the meeting.

9.3. Dr Iain Squire declared a non-personal specific financial interest as he has received honoraria from Novartis for participation in advisory Boards and Educational events. My Department is in receipt of financial support to fund research from Novartis

9.3.1 It was agreed that this declaration would not prevent Professor Iain Squire from participating in this section of the meeting.

10. The Chair asked all NICE Staff to declare any relevant interests.

10.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Fulvestrant for untreated hormone-receptor positive locally advanced or metastatic breast cancer [ID951]

11. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

11.1. Keith Cooper, Mrs Gwyneth Fraser, Joanne Picot, Neelam Kalita and Catherine Priestly declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Fulvestrant for untreated hormone-receptor positive locally advanced or metastatic breast cancer [ID951].

11.2. Dr Daniel Rea declared a personal non-specific financial interest for teaching Astrazeneca Sales Force on management of adjunct breast cancer and Honoraria paid to charities

11.2.1. It was agreed that this declaration would not prevent Dr Daniel Rea from participating in this section of the meeting

12. The Chair introduced the lead team, Dr Rachel Hobson and Professor Olivia Wu who gave presentations on the clinical effectiveness and cost effectiveness of
Fulvestrant for untreated hormone-receptor positive locally advanced or metastatic breast cancer [ID951].

13. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

14. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

15. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

16. Discussion on confidential information continued. This information was supplied by the company.

17. The Committee continued to discuss the clinical and cost effectiveness of Fulvestrant for untreated hormone-receptor positive locally advanced or metastatic breast cancer [ID951].

18. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Date, time and venue of the next meeting

19. Tuesday 5 September 2017, 10am at Prospero House, 241 Borough High Street, SE1 1GA